최소 단어 이상 선택하여야 합니다.
최대 10 단어까지만 선택 가능합니다.
다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기한국임상약학회지 = Korean journal of clinical pharmacy, v.31 no.1, 2021년, pp.53 - 60
이보미 (성균관대학교 약학대학) , 박상준 (성균관대학교 약학대학) , 심다영 (성균관대학교 약학대학) , 이하은 (성균관대학교 약학대학) , 이정은 (성균관대학교 약학대학) , 김상희 (성균관대학교 약학대학) , 조혜경 (성균관대학교 약학대학) , 신주영 (성균관대학교 약학대학)
Objective: To gather the opinions of hands-on workers for successful introduction of the Development Safety Update Report (DSUR) according to a five-year comprehensive plan for clinical trial development [Ministry of Food and Drug Safety, 2019]. Methods: We conducted a survey on considerations that ...
* AI 자동 식별 결과로 적합하지 않은 문장이 있을 수 있으니, 이용에 유의하시기 바랍니다.
The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. ICH Harmonised tripartite guideline, Development safety update report E2F, current step 4 version. Available from https://database.ich.org/sites/default/files/E2F_Guideline.pdf. Accessed November 27, 2020.
Ministry of Food and Drug Safety. 2019 drug clinical trial approval status and safety management policy announced September 3, 2020. Available from https://www.mfds.go.kr/brd/m_99/view.do?seq44570. Accessed December 2, 2020.
Korea Clinical trials Information Center. Status of Domestic Clinical Trial announced March 27, 2019. Available from https://www.koreaclinicaltrials.org/kr/contents/datainfo_data_01_tab02/view.do. Accessed December 3, 2020.
The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. Efficacy Guidelines (E2F) Implementation status. Available from https://ich.org/page/efficacy-guidelines. Accessed March 27, 2020.
Korea Ministry of Government Legislation: National law information center. Available from https://www.law.go.kr/법령/의약품등의안전에관한규칙/(20201014,01650,20201014)/제30조. Accessed December 3, 2020.
Ministry of Food and Drug Safety (MFDS). Five-year Comprehensive plan for development of clinical trial. Available from https://www.mfds.go.kr/docviewer/skin/doc.html?fn20190808095119126.hwp&rs/docviewer/result/ntc0021/43629/3/202011. Accessed December 2, 2020.
Ministry of Food and Drug Safety (MFDS). 2020 Plan for GCP inspection. Available from https://nedrug.mfds.go.kr/bbs/38/100/. Accessed December 4, 2020.
Shin JY, A Study on Developing Drug Safety Report Management and Guideline of Development Safety Update Report(DSUR) for Investigational Product MFDS final report (20172의약안160) October 26, 2020. MFDS, in press.
Biotech Information Portal. Statistics on the status of domestic bio start-up companies in 2017. Available from https://www.bioin.or.kr/board.do?num284415&cmdview&bidessay&cPage1&cate1all&cate2all2. Accessed December 6, 2020.
Clinical Trial Facilitation Group (European Medicines Agency). Questions and Answers to the Annual Safety Report Frequently asked questions regarding the Development Safety Update Report (DSUR). Available from https://www.hma.eu/fileadmin/dateien/Human_Medicines/01-About_HMA/Working_Groups/CTFG/2011_12_22_Q_A_DSUR.pdf. Accessed September 17, 2020.
Electronic Code of Federal Regulations. Investigational New Drug Applications. Available from https://www.ecfr.gov/cgi-bin/textidx?SID96a1ee76b6bafe54d48b35165eae9d34&mctrue&nodese21.5.320_131&rgndiv8. Accessed October 14, 2020.
Ministry of Food and Drug Safety (MFDS). Drug Approval report 2018. Available from https://www.mfds.go.kr/brd/m_99/view.do?seq43642&srchFr&srchTo&srchWord&srchTp&itm_seq_10&itm_seq_20&multi_itm_seq0&company_cd&company_nm&page1. Accessed December 4, 2020.
U.S. Food and Drug Administration. Guidance for Industry and Investigators: Safety Reporting Requirements for INDs and BA/BE Studies. Available from https://www.fda.gov/media/79394/download. Accessed December 9, 2020.
Korea Ministry of Government Legislation: National law information center. Available from https://www.law.go.kr/법령/의약품등의안전에관한규칙/(20201014,01650,20201014)/제30조 11항 10호. Accessed October 10, 2020.
European Commission DIRECTIVE 2001/20/EC, The European parliament and of the council of 4 April 2001.Available from https://eur-lex.europa.eu/legal-content/EN/TXT/?uriCELEX:52010XC0330(01). Accessed October 14, 2020.
The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. ICH Harmonised tripartite guideline. Periodic Benefit-Risk Evaluation Report, E2C (R2), Current Step 4 version. Available from https://database.ich.org/sites/default/files/E2C_R2_Guideline.pdf. Accessed March 27, 2020.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.